Molecular structure of Marimastat, CAS Number: 154039-60-8
Marimastat (CAS 154039-60-8)
See product citations (19)
Alternate Names:
Marimastat is also known as BB2516.
Application:
Marimastat is a broad spectrum MMP inhibitor and selective TACE inhibitor that can inhibit lymph node metastasis in carcinoma models.
CAS Number:
154039-60-8
Purity:
≥98%
Molecular Weight:
331.41
Molecular Formula:
C15H29N3O5
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Marimastat (BB-2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor with specificity towards MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 and IC50 values of 3, 5, 6, 9 and 13 nM respectively. MMPs are a homologous family of enzymes involved in tissue remodeling and morphogenesis, where collectively, these enzymes are capable of degrading all components of the extracellular matrix, and they play an important role in wound healing and other processes involving tissue remodeling. Research shows that Marimastat inhibits CD30 shedding in Karpas 299 cells with an IC50 of 1 microM and also inhibits lipopolysaccharide (LPS)-induced soluble TNF-alpha production in a dose-dependent manner. The enzyme Tumor necrosis factor alpha convertase (TACE), reported to be closely related to matrix metalloproteinases, is responsible for the processing of pro-TNFalpha to TNFalpha and is specifically inhibited by Marimastat with an IC50 of 3.8 nM. Studies show that Marimastat, as a peptide hydroxamate compound, also inhibits peritoneal dissemination of human gastric cancer cells through tumor angiogenesis inhibition.
Marimastat (CAS 154039-60-8) References
- Marimastat (BB2516): current status of development. | Steward, WP. 1999. Cancer Chemother Pharmacol. 43 Suppl: S56-60. PMID: 10357560
- New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors. | Barlaam, B., et al. 1999. J Med Chem. 42: 4890-908. PMID: 10579851
- Marimastat: the clinical development of a matrix metalloproteinase inhibitor. | Steward, WP. and Thomas, AL. 2000. Expert Opin Investig Drugs. 9: 2913-22. PMID: 11093361
- Design and therapeutic application of matrix metalloproteinase inhibitors. | Whittaker, M., et al. 1999. Chem Rev. 99: 2735-76. PMID: 11749499
- Inhibition of metalloproteinases enhances the internalization of anti-CD30 antibody Ki-3 and the cytotoxic activity of Ki-3 immunotoxin. | Hansen, HP., et al. 2002. Int J Cancer. 98: 210-5. PMID: 11857410
- Differential effects between marimastat, a TNF-alpha converting enzyme inhibitor, and anti-TNF-alpha antibody on murine models for sepsis and arthritis. | Tsuji, F., et al. 2002. Cytokine. 17: 294-300. PMID: 12061836
- Marimastat: BB 2516, TA 2516. | . 2003. Drugs R D. 4: 198-203. PMID: 12757409
- Reduced angiogenesis in peritoneal dissemination of gastric cancer through gelatinase inhibition. | Wada, N., et al. 2003. Clin Exp Metastasis. 20: 431-5. PMID: 14524532
- Matrix metalloproteinases participate in osteosarcoma invasion. | Bjørnland, K., et al. 2005. J Surg Res. 127: 151-6. PMID: 16083752
- An in vitro model that can distinguish between effects on angiogenesis and on established vasculature: actions of TNP-470, marimastat and the tubulin-binding agent Ang-510. | van Wijngaarden, J., et al. 2010. Biochem Biophys Res Commun. 391: 1161-5. PMID: 20004648
- The matrix metalloproteinase inhibitor marimastat inhibits seizures in a model of kainic acid-induced status epilepticus. | Pijet, B., et al. 2020. Sci Rep. 10: 21314. PMID: 33277582
- Marimastat alleviates oxidative stress induced cellular senescence by activating autophagy. | Xia, J., et al. 2022. Biochem Biophys Res Commun. 620: 121-128. PMID: 35780580
- Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. | Rasmussen, HS. and McCann, PP. 1997. Pharmacol Ther. 75: 69-75. PMID: 9364582
Inhibitor of:
α-parvin, α2-Macroglobulin, α2ML1, 2900024O10Rik, 5430419D17Rik, ADAM, ADAM11, ADAM18, ADAM2, ADAM20, ADAM21, ADAM23, ADAM24, ADAM25, ADAM26, ADAM26B, ADAM29, ADAM30, ADAM32, ADAM34, ADAM38, ADAM39, ADAM6A, ADAM6B, ADAM7, ADAMTS-13, ADAMTS-19, ADAMTS-20, ADAMTS-8, ADAMTS-9, ADAMTS-L5, Aminopeptidase B-L1, AMZ1, apoL7a, apoL7c, apoL7e, BC048546, C8γ, CACHD1, cadherin-16, cadherin-29, Calpactin, CCDC38, CCP4, CD9P-1, CEACAM16, CEACAM3, CLAP, COL12A1, COL14A1, COL1A1, COL21A1, COL22A1, COL23A1, COL4A5, COL6A3, COL6A4, COL9A1, Collagen α1, CPA4, CPA5, CPM, CPXM2, Ddc8, Dispase I, Ear11, EG245297, EG384813, EG665186, EGFL11, EGFL3, EGFL8, EMID1, EMID2, EMILIN-2, FAM90A1, FBF1, fibrillin-3, Fibulin-7, Filamin β, granzyme A, granzyme D, granzyme F, HB-EGF, hemicentin-2, HKIB9, Hmcn2, Integrin αE, Integrin β6, ISLR, ITBA1, ITFG3, JAM (junction adhesion molecule), KIAA0247, Kininogen II, KLK (Kallikrein related peptidase), Klkb21, Klkb22, LAD1, laeverin_4833403I15Rik, Laminin β-2, Laminin γ-3, LEAP-2, LMLN, LOC150356, LOC150935, LRRIQ1, LTBP, LTBP-2, LUZP2, LYPD1, M-ficolin, Mast Cell Protease, Mast Cell Protease 4, Mast Cell Protease 7, Mast Cell Protease 9, Matriptase, Matriptase-2, MBLAC2, MCC, megsin, melusin, Meprin A, Meprin A alpha, Meprin Aβ, METH-1, MICB, Microfibril associated protein (MFAP), MMP, MMP-1, MMP-10, MMP-1a, MMP-1b, MMP-2, MMP-20, MMP-7, MMP-8, MMP-9, MSY3, MT-MMP-1, murinoglobulin 1, murinoglobulin 2, MXRA5, MXRA7, MYL10, Myosin-13, N-RAP, NAALAD2, NAALADL2, Nebulette, NET-7, Ninjurin-2, nov, ORAOV1, otoancorin, OTTMUSG00000008561, OTTMUSG00000016293, OVCA2, P1 Adhesion, Papilin, PCDHA11, PCDHGB1, PCPE-1, PDP2, PF4V1, PHEX, pilD, POEM, PRG-3, prochymosin, Proliferin-1, Proliferin-4, PRSS37, Psg16, rat endothelium, RBMS3, RHBDL2, Rhomboid, SCGB1D4, Sel-1L3, SerpinA11, SerpinA2, SerpinB11, Serpinb6d, SerpinB6e, SIAH-2, spectrin β II, SPINK10, SPINK3, SPINK7, SPUVE, SSc5D, SUSD2, Syne-4, TACE, TATI, Tenascin-R, Testican-2, THSD3, TIMP-1, TIMP-2, TIMP-3, TIMP-4, TIN-Ag, TLCK, TLL1, TLL2, TMPRSS11A, TMPRSS11B, TMPRSS11F, TMPRSS5, TNFa-IP 8, TPSB1, TPSB3, Tryptase, Tryptase γ, Vmn2r50, Vmn2r62, Vmn2r70, Vrho, VWA5B2, VWA8, WARP, WECHE, WFDC17, and ZPLD1.Activator of:
ADAM21, ADAM24, ADAM25, ADAM8, Cas-L, CMG1, COL6A3, Elastase-3, FRAS1, FSD1, LMLN, Meprin A, MMP-19, MMP-1b, MT-MMP-4, MT-MMP-6, NPEPL1, PCDHA9, Relaxin 1, Testican-1, TIFAB, and TMPRSS7.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Marimastat, 5 mg | sc-202223 | 5 mg | $165.00 | |||
Marimastat, 10 mg | sc-202223A | 10 mg | $214.00 | |||
Marimastat, 25 mg | sc-202223B | 25 mg | $396.00 | |||
Marimastat, 50 mg | sc-202223C | 50 mg | $617.00 | |||
Marimastat, 400 mg | sc-202223E | 400 mg | $4804.00 |